TB REACH WAVE 9

In 2021, UZT was among recipients of the Stop TB Partnership Wave 9 funding awarded to **11** projects across **8** countries, focusing on innovative approaches to address Drug Resistant TB (DR-TB).

With support from USAID and Global Affairs Canada, the investments supported scale-up of newer and shorter all-oral regimens for DR-TB, through the introduction of Xpert MTB/XDR assay for early detection of second-line drug resistance.

In Zimbabwe, the project was implemented in **19** high burden districts across Bulawayo, Matebeleland South and Midlands provinces, with a buy-in of **US$600 000** over the 2-year project life-span. The project goal was to treat all people with DR-TB with specific objectives to:

1. *To provide DST for FQ to at least 90% of patients detected with MDR/RR-TB*
2. *To enroll at least 183 (100%) detected DR-TB patients on treatment*
3. *To enroll at least 165 (90%) DR-TB patients on an all oral regimen*
4. *To ensure a treatment success rate of at least 80% among DR-TB patients initiating treatment*




BCC